These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 19558256)

  • 1. Pharmacogenetics of selective serotonin reuptake inhibitors and associated adverse drug reactions.
    Thomas KL; Ellingrod VL
    Pharmacotherapy; 2009 Jul; 29(7):822-31. PubMed ID: 19558256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin Transporter Gene Polymorphisms and Selective Serotonin Reuptake Inhibitor Tolerability: Review of Pharmacogenetic Evidence.
    Zhu J; Klein-Fedyshin M; Stevenson JM
    Pharmacotherapy; 2017 Sep; 37(9):1089-1104. PubMed ID: 28654193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the pharmacogenetics of selective serotonin reuptake inhibitors.
    Fabbri C; Minarini A; Niitsu T; Serretti A
    Expert Opin Drug Metab Toxicol; 2014 Aug; 10(8):1093-118. PubMed ID: 24930681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacogenomics of selective serotonin reuptake inhibitors.
    Serretti A; Artioli P
    Pharmacogenomics J; 2004; 4(4):233-44. PubMed ID: 15111987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights and barriers to clinical use of serotonin transporter pharmacogenetics in antidepressant therapy.
    Stevenson JM
    Pharmacogenomics; 2018 Feb; 19(3):167-170. PubMed ID: 29325499
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacogenetics of psychotropic drug response.
    Malhotra AK; Murphy GM; Kennedy JL
    Am J Psychiatry; 2004 May; 161(5):780-96. PubMed ID: 15121641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Could pharmacogenetics play a role as predictor in treatment of depressive disorders?
    Lee MS
    World J Biol Psychiatry; 2007; 8(1):2-3. PubMed ID: 17366343
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy.
    Steimer W; Müller B; Leucht S; Kissling W
    Clin Chim Acta; 2001 Jun; 308(1-2):33-41. PubMed ID: 11412815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which adverse effects influence the dropout rate in selective serotonin reuptake inhibitor (SSRI) treatment? Results for 50,824 patients.
    Kostev K; Rex J; Eith T; Heilmaier C
    Ger Med Sci; 2014; 12():Doc15. PubMed ID: 25332703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of pharmacogenomics in individualising treatment with SSRIs.
    Mancama D; Kerwin RW
    CNS Drugs; 2003; 17(3):143-51. PubMed ID: 12617694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial.
    Garfield LD; Dixon D; Nowotny P; Lotrich FE; Pollock BG; Kristjansson SD; Doré PM; Lenze EJ
    Am J Geriatr Psychiatry; 2014 Oct; 22(10):971-9. PubMed ID: 24021217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of selective serotonin reuptake inhibitors in pediatric depression and anxiety.
    Kronenberg S; Frisch A; Rotberg B; Carmel M; Apter A; Weizman A
    Pharmacogenomics; 2008 Nov; 9(11):1725-36. PubMed ID: 19018726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suicidality with selective serotonin reuptake inhibitors: Valid claim?
    Lapierre YD
    J Psychiatry Neurosci; 2003 Sep; 28(5):340-7. PubMed ID: 14517577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Selective serotonin reuptake inhibitor(SSRI)].
    Motohashi N
    Nihon Rinsho; 2001 Aug; 59(8):1519-22. PubMed ID: 11519151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drop-out rates in placebo-controlled trials of antidepressant drugs: A systematic review and meta-analysis based on clinical study reports.
    Sharma T; Guski LS; Freund N; Meng DM; Gøtzsche PC
    Int J Risk Saf Med; 2019; 30(4):217-232. PubMed ID: 31561390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials.
    Barth M; Kriston L; Klostermann S; Barbui C; Cipriani A; Linde K
    Br J Psychiatry; 2016 Feb; 208(2):114-9. PubMed ID: 26834168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review.
    Lane R; Baldwin D
    J Clin Psychopharmacol; 1997 Jun; 17(3):208-21. PubMed ID: 9169967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents.
    Hetrick S; Merry S; McKenzie J; Sindahl P; Proctor M
    Cochrane Database Syst Rev; 2007 Jul; (3):CD004851. PubMed ID: 17636776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do Maternal Pharmacogenetics Impact the Neonatal Abstinence Syndrome Following In Utero Exposure to Antidepressant Medications?
    Shea AK; Wang DY; Snelgrove JW; Dalfen A; Hewko S; Murphy KE
    J Obstet Gynaecol Can; 2021 Jun; 43(6):726-732. PubMed ID: 33303407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin-norepinephrine reuptake inhibitor and selective serotonin reuptake inhibitor use and risk of fractures: a new-user cohort study among US adults aged 50 years and older.
    Lanteigne A; Sheu YH; Stürmer T; Pate V; Azrael D; Swanson SA; Miller M
    CNS Drugs; 2015 Mar; 29(3):245-52. PubMed ID: 25708711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.